Page 179 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 179
Rituximab intensification during R-CHOP in DLBCL Table A2. Multivariable Analysis of Prognostic Factors for DFS From CR.
Factor HR
RR-CHOP-14 arm 1.24 Age ≥ 66 years 1.77 Age-adjusted IPI scorea 1.14 Female sex 1.02 WHO performance scoreb 0.99 LDH > ULN 1.50 B symptoms 1.04 Bulky disease 0.94 BM involvement 1.34
95% CI P 0.93 to 1.66 .14 1.30 to 2.40 <.001 0.81 to 1.60 .45 0.76 to 1.37 .89 0.76 to 1.28 .92 0.93 to 2.42 .10 0.76 to 1.42 .82 0.68 to 1.31 .72 0.89 to 2.03 .16
Abbreviations: BM, bone marrow; CR, complete remission; DFS, disease-free survival; HR, hazard ratio; IPI, International Prognostic Index; LDH, lactate dehydrogenase; RR-CHOP, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B); ULN, upper limit of normal.
aAnalyzed as low v low-intermediate v high-intermediate v high. bAnalyzed as WHO 0 v 1 v 2.
177
6b
